Search clinical trials for: sapacitabine and seliciclib

Total 270946 results

Cyclacel Pharmaceuticals, Inc.

Completed

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Cyclacel Pharmaceuticals, Inc.

Completed

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Acute Myeloid Leukemia

United States
University Hospital, Brest
Cyclacel Pharmaceuticals, Inc.; ManRos Therapeutics

Terminated

Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF)

Cystic Fibrosis

France
Cyclacel Pharmaceuticals, Inc.

Terminated

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Cedars-Sinai Medical Center

Recruiting

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

Cushing Disease

United States
Shlomo Melmed, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Terminated

Treatment of Cushing's Disease With R-roscovitine

Cushings Disease

United States
Cyclacel Pharmaceuticals, Inc.

Terminated

A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Cyclacel Pharmaceuticals, Inc.

Completed

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemias

United States
M.D. Anderson Cancer Center
National Institutes of Health (NIH)

Withdrawn

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Breast Cancer
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Unknown

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Sun Yat-sen University
Chengdu Biostar Pharmaceuticals

Not yet recruiting

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms | Locally Advanced or Metastatic Breast Cancer

China
Cyclacel Pharmaceuticals, Inc.

Terminated

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL)

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

Breast Neoplasms

China
Hoffmann-La Roche

Completed

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

Breast Cancer, Colorectal Cancer

New Zealand, Australia, United Kingdom
Fudan University

Completed

Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage

Gastric Cancer

China
Jules Bordet Institute

Completed

Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study

Breast Cancer | Elderly Patients

Belgium
Jiangxi Provincial Cancer Hospital

Recruiting

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer

China
Binghe Xu
Hoffmann-La Roche

Unknown

Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC (CAMELLIA)

Skin Diseases | Neoplasms by Site | Breast Neoplasms | Breast Diseases | Neoplasm Metastasis

China
Samsung Medical Center

Completed

Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma

Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Korea, Republic of
Samsung Medical Center

Completed

A Study of Pazopanib With CAPEOX in AGC Patients

Gastric Cancer

Korea, Republic of
Samsung Medical Center
National Cancer Center, Korea; Asan Medical Center; Chonnam National University... and other collaborators

Completed

Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer

Colorectal Cancer

Korea, Republic of
Hebei Medical University

Completed

Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction (A-C)

Gastroesophageal Junction Adenocarcinoma

China
Shandong Cancer Hospital and Institute

Not yet recruiting

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Metastatic Breast Cancer
Huazhong University of Science and Technology

Unknown

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Gastric Cancer

China
Swiss Group for Clinical Cancer Research

Completed

Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Prostate Cancer

Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Capecitabine in Treating Patients With Malignant Mesothelioma

Malignant Mesothelioma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Cervical Cancer

United States, Norway
Korea University Anam Hospital

Not yet recruiting

Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Recurrent or Metastatic Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy...
Hoffmann-La Roche

Unknown

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Carcinoma, Invasive Ductal, Breast

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
The Affiliated Hospital of the Chinese Academy...

Unknown

Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction

Gastric Cancer

China
Swiss Group for Clinical Cancer Research

Completed

Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Colorectal Cancer

Switzerland
University of Rochester

Recruiting

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Breast Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)

Breast Cancer

China
University of Southern California
National Cancer Institute (NCI)

Recruiting

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER)

Cancer | Metastatic | Breast | Triple Negative | Disseminated Tumor Cell

United States
National Cancer Institute, Naples

Completed

MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer

Ovarian Cancer

Italy
Pharmatech Oncology

Unknown

Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

Pancreatic Cancer

Spain, United States
Association Pour La Recherche des Thérapeutiques...

Unknown

Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen

Breast Neoplasms | Chemotherapy

France
Processa Pharmaceuticals

Recruiting

A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors

Advanced Cancer | Refractory Cancer | Tumor Gastric

United States
Odonate Therapeutics, Inc.

Terminated

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)

Breast Cancer

Korea, Republic of, United States, Spain, Canada, Singapore, Taiwan, Australia, Belgium, Thailand, Hungary, Germany, United Kingdom, France, Ukraine, Austria, Czechia, Italy, Poland, Russian Federation
AIO-Studien-gGmbH
iOMEDICO AG

Terminated

Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer (VOXEL)

Colorectal Neoplasms

Germany
Fujian Medical University Union Hospital

Not yet recruiting

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

Advanced Breast Cancer
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

China
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Advanced Cervical Cancer

China
Asan Medical Center
Ulsan University Hospital; Seoul National University Bundang Hospital; Gachon... and other collaborators

Recruiting

Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

Gastric Cancer

Korea, Republic of
Hoffmann-La Roche

Terminated

A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer

Breast Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Withdrawn

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

Breast Cancer

Search clinical trials for: sapacitabine and seliciclib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations